Hanmi Pharm Approaches 1 Trillion KRW in Cumulative Sales for Q3 This Year... "Expecting Record-Breaking Performance"

Q3 Sales of 342.1 Billion KRW, Operating Profit of 46.8 Billion KRW
Strong Performance in Outpatient Prescription Market and Beijing Hanmi Driving Growth

Hanmi Pharmaceutical Headquarters. [Photo by Hanmi Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical's cumulative sales from the first to the third quarter this year are approaching 1 trillion KRW, and it is expected to achieve the highest performance in its history this year.

Hanmi Pharmaceutical announced on the 1st that its consolidated sales for the third quarter reached 342.1 billion KRW, a 12.9% increase compared to the same period last year. Operating profit and net profit grew by 26.9% and 11.5%, respectively, amounting to 46.8 billion KRW and 31.3 billion KRW. The company invested 45.3 billion KRW in research and development (R&D), which accounts for 13.3% of sales.

Hanmi Pharmaceutical explained, "Excluding overseas technology royalties, quarterly sales exceeding 340 billion KRW is the first time since the company's founding." Hanmi Pharmaceutical achieved sales of 321.1 billion KRW in the first quarter and 317.1 billion KRW in the second quarter this year, and with third-quarter sales of 342.1 billion KRW, the cumulative sales for the three quarters reached 980.3 billion KRW.

Hanmi Pharmaceutical's strong performance is analyzed to be due to explosive growth of its local Chinese subsidiary, Beijing Hanmi Pharmaceutical, as well as domestic outpatient prescription sales. Hanmi Pharmaceutical's key combination drugs such as the Amozantan family, Rosuzet, and Esomezol family have been steadily growing every year. In particular, the cumulative prescription amount for the first three quarters of Rosuzet, a combination drug for dyslipidemia treatment, increased by 13.3% compared to the same period last year, reaching 103 billion KRW. Hanmi Pharmaceutical's products recorded the highest prescription sales of 585.9 billion KRW among domestic pharmaceutical companies up to the third quarter this year. Thanks to this trend, Hanmi Pharmaceutical is expected to achieve first place in the domestic outpatient prescription market for the fifth consecutive year by the end of this year.

Beijing Hanmi Pharmaceutical led the strong performance by achieving sales of 93 billion KRW, operating profit of 24.2 billion KRW, and net profit of 22.2 billion KRW in the third quarter. Beijing Hanmi Pharmaceutical's sales grew by 23.4%, operating profit by 25.5%, and net profit by 15.7% compared to the same period last year.

This performance is being reinvested in R&D for future value. Hanmi Pharmaceutical is currently developing more than 20 global innovative new drugs, and in September, it received marketing approval from the U.S. Food and Drug Administration (FDA) for Rolontis, a new drug for neutropenia.

A Hanmi Pharmaceutical official said, "We are proving the vision of this year's management slogan, 'Sustainable Innovation Management,' through excellent performance," adding, "We will do our best to present a management model that the Korean pharmaceutical and bio industry should follow and to contribute to achieving a strong pharmaceutical nation as a native pharmaceutical company."

This content was produced with the assistance of AI translation services.